Abstract: This technology relates to a method of treating breast cancer in a subject and a method of determining whether a breast lesion in a subject is malignant or benign using miRNA panels.

Abstract: Provided are peripheral blood miRNA markers for diagnosis of non-small cell lung cancer, wherein the peripheral blood miRNA markers comprise hsa-miR-1291, hsa-miR-1-3p, hsa-miR-214-3p, hsa-miR-375 or hsa-let-7a-5p. Five specific diagnostic markers suitable for diagnosing non-small cell lung cancer in Asian and Caucasian populations are validated on a large number of samples, and have higher population specificity compared to other miRNA markers previously reported. These five miRNA diagnostic markers are proposed for the first time and are shown to be more reliable than other miRNA molecular markers.

Abstract: Present application relates to methods for determining whether a subject has heart failure or is at risk of having heart failure, specifically that of heart failure with reduced left ventricular ejection fraction (HFREF) and a heart failure with preserved left ventricular ejection fraction (HFPEF), comprising determining the level of selected miRNA(s) observed in a sample obtained from the subject and wherein an altered level of the miRNA(s) compared to control indicates that the subject has heart failure or is at risk of developing heart failure. Also encompassed are methods of determining an altered risk of death or disease progression to hospitalization and death based on alteration of selected miRNAs in a sample from the subject and kits thereof.

Abstract: Disclosed are methods of determining the likelihood of a subject having or developing a gastric cancer. The methods comprise measuring the expression level of at least one miRNA having at least 90% sequence identity with an miRNA as described herein in a non-cellular biofluid sample obtained from the subject, wherein differential expression of miRNA expression in the sample obtained from the subject, as compared to a control, may be indicative of the subject having gastric cancer and wherein the miRNA may be either an miRNA listed as “up-regulated” or an miRNA listed as “down-regulated”. Also disclosed is a method of determining the likelihood of a subject having or developing a stage of a gastric cancer.

Abstract: A high-voltage earthing switch is disclosed. A static contact of the earthing switch is connected with the first end of a conductive copper busbar. The second end of the conductive copper busbar is connected with a transformer. The conductive copper busbar includes a first segment and a second segment connected with the first segment. The first segment is one straight segment and an end is taken as an end of the first end of the conductive copper busbar. The first segment extends from the static contact in the direction opposite to the instantaneous action direction of the moving contact when the moving contact engages the static contact. The second segment is connected with the other end of the first segment, and extends towards the side of the first segment facing away from the moving contact.

Abstract: The present invention relates to a composition for transfecting a cell with a genetic material comprising a first agent capable of directing the genetic material away from the acidic compartments in the cell and a second agent capable of stabilizing the microtubule or a network thereof. The invention also relates to the use of the composition in the manufacture of a medicament for treating a disease, a method for delivering a genetic material into a cell and a kit.

Abstract: The present disclosure describes methods of determining the risk of developing breast cancer in a subject or determining whether a subject suffers from breast cancer. The methods can comprise detecting the expression level of microRNAs (miRNAs) hsa-miR-186-5p (SEQ ID NO: 77) and/or hsa-miR-409-3p (SEQ ID NO: 178) in a bodily fluid sample obtained from the subject and determining whether it is upregulated or downregulated as compared to a control, wherein the upregulation of hsa-miR-186-5p (SEQ ID NO: 77) and/or downregulation of hsa-miR-409-3p (SEQ ID NO: 178) indicates that the subject has breast cancer or is at risk of developing breast cancers. Also encompassed are methods of prognosis or diagnosis of breast cancer by detecting expression levels of combinations of miRNAs and using a score based on a panel of miRNA markers.

Abstract: A high-voltage earthing switch is disclosed. A static contact of the earthing switch is connected with the first end of a conductive copper busbar. The second end of the conductive copper busbar is connected with a transformer. The conductive copper busbar includes a first segment and a second segment connected with the first segment. The first segment is one straight segment and an end is taken as an end the first end of the conductive copper busbar. The first segment is parallel to the instantaneous action direction of the moving contact when a moving contact engages the static contact. The first segment extends from the static contact in the direction opposite to the instantaneous action direction of the moving contact when the moving contact engages the static contact. The second segment is connected with the other end of the first segment, and extends towards the side of the first segment facing away from the moving contact.

Abstract: Present application relates to methods for determining whether a subject has heart failure or is at risk of having heart failure, specifically that of heart failure with reduced left ventricular ejection fraction (HFREF) and a heart failure with preserved left ventricular ejection fraction (HFPEF), comprising determining the level of selected miRNA(s) observed in a sample obtained from the subject and wherein an altered level of the miRNA(s) compared to control indicates that the subject has heart failure or is at risk of developing heart failure. Also encompassed are methods of determining an altered risk of death or disease progression to hospitalization and death based on alteration of selected miRNAs in a sample from the subject and kits thereof.

Abstract: Disclosed are methods of determining the likelihood of a subject having or developing a gastric cancer. The methods comprise measuring the expression level of at least one miRNA having at least 90% sequence identity with an miRNA as described herein in a non-cellular biofluid sample obtained from the subject, wherein differential expression of miRNA expression in the sample obtained from the subject, as compared to a control, may be indicative of the subject having gastric cancer and wherein the miRNA may be either an miRNA listed as “up-regulated” or an miRNA listed as “down-regulated”. Also disclosed is a method of determining the likelihood of a subject having or developing a stage of a gastric cancer.

Abstract: The present invention relates to a composition for transfecting a cell with a genetic material comprising a first agent capable of directing the genetic material away from the acidic compartments in the cell and a second agent capable of stabilizing the microtubule or a network thereof. The invention also relates to the use of the composition in the manufacture of a medicament for treating a disease, a method for delivering a genetic material into a cell and a kit.

Abstract: There is provided a microarray comprising a plurality of active agents immobilized onto an array of porous nanostructures, wherein each nanostructure has a network of pores that extends throughout the thickness of said nano structure.